Thought Leader Liaison; TLL - West

Tonix is a fully integrated biotechnology company, publicly traded on NASDAQ (ticker: TNXP), with marketed products and a pipeline of development candidates. The Company is focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease. In August 2025, Tonix received FDA approval for Tonmya™ (cyclobenzaprine HCl sublingual tablets), a first-in-class, once-daily, non-opioid treatment for fibromyalgia. Tonmya is the first new fibromyalgia therapy approved in over 15 years, following successful Phase 3 trials demonstrating significant symptom improvement.

Commercial launch is expected in the fourth quarter of 2025.

Tonix also markets Zembrace® Sym Touch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg, both indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio includes product candidates in central nervous system (CNS), immunology, immuno-oncology infectious disease and rare disease. The CNS pipeline features both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.

The immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. The infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, which also serves as a live virus vaccine platform for other infectious diseases. Finally, the rare disease portfolio includes a product in development for Prader-Willi syndrome, which has both orphan drug designation and rare pediatric disease designation grants from the FDA.

Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

Please visit  for specifics on the pipeline.

All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

The Associate Director Thought Leader Liaison (TLL), Fibromyalgia, will directly report into the Director, Commercial Strategy and will lead executional efforts in regional and local engagement with existing and emerging Key Opinion Leaders (KOLs), Advocacy Groups and Professional Societies to develop and implement education that helps simplify the early Fibromyalgia patient journey from diagnosis through treatment and monitoring. This will include identifying new and emerging opinion leaders and appropriately engaging KOLs to support speaker bureau activities, and assessing speaker programs for meaningfulness, effectiveness, education, and compliance with company policies.

The TLL role is a field-based role (non-sales focused) position, working closely with U.S. Key Fibromyalgia Thought Leaders (KOLs) to ensure cross-functional commercial resources are made available as appropriate. The three primary (but not exclusive) areas of focus for TLL are KOL engagement, executive encounter management, and supporting the Fibromyalgia community.

• KOL engagement – identify, profile, and maintain long-term relationships with KOLs in the Fibromyalgia community
• Engagement with national, regional, and local thought leaders, including emerging thought leaders, to identify and seek insight regarding best practices that can help simplify the patient journey
• Identification and implementation of training (product, disease state, and compliance training) for promotional speakers and related aspects of speaker programs
• Collaboration with Promotional Program Manager for speaker usage and issues
• Provide feedback regarding nomination of new speakers, when applicable
• Coordinate/facilitate new product and annual compliance training for speakers
• Work with Marketing team for annual speaker re-contracting
• Update and track KOL engagements via KOL management platform in partnership with operations lead
• Collaborate appropriately with field teams to enable local/account-level engagement with national, regional, and emerging thought leaders
• Facilitate coordination of KOL engagements at the local level
• Coordinate with field sales team, brand leads, and speaker program vendor on speaker availability and utilization
• Ensure appropriate…